Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nitrofurantoin

FDA-approved product (tablet, oral), marketed as Furadantin, Furalan, Nitrofurantoin and 3 more.

Registered studies
50+
Lab records
6
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nitrofurantoin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Cystitis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nitrofuran derivatives
FDA pharmacologic class
Nitrofuran Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XE01; WHO ATC J01XE51; FDA class Nitrofuran Antibacterial

Repurposing investigation

Nitrofurantoin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli31.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis92.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 0 of 4 lab records
  • M. tuberculosis: measured active in 1 of 2 lab records
Open Nitrofurantoin in ChEMBL Registered studies below
Show the 6 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nitrofurantoin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Immunological Disorders of T Lymphocytes and Endocrinological Disorders as Pathogen Factors in Patients With Metaplasia of Urinary Bladder

    NCT02092558 · start 2005-01

    Registered record
    Registry ID
    NCT02092558
    Conditions
    The Follow-up Duration Was 1-8 Years.; The Main Reasons Behind Visiting the Hospital Were Recurrent Urinary Tract Infection,; Urinary Urgencies, Pollakiuria, Difficulty in Initiating Micturition, Pain in Hypogastrium,; Night Wetting and Day Wetting, Menstruation's Disorders, Urolithiasis, Defects of Urinary; System and Hematuria.
    Interventions
    Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution; cephalosporin with chemotherapeutics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-01
    Completion
    2013-12
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Follow-up Duration Was 1-8 Years.; The Main Reasons Behind Visiting the Hospital Were Recurrent Urinary Tract Infection,; Urinary Urgencies, Pollakiuria, Difficulty in Initiating Micturition, Pain in Hypogastrium,; Night Wetting and Day Wetting, Menstruation's Disorders, Urolithiasis, Defects of Urinary +1 more
    InterventionSecond-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution; cephalosporin with chemotherapeutics
    PhaseNot recorded
    Registry statusCompleted

  • Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

    NCT00141037 · start 2004-03

    Registered record
    Registry ID
    NCT00141037
    Conditions
    Kidney Diseases; Kidney Transplantation; Kidney Transplant; Renal Transplantation; Renal Transplant
    Interventions
    Daclizumab; Mycophenolate mofetil (MMF); Prednisone; Tacrolimus; Ganciclovir; Valganciclovir; Trimethoprim and sulfamethoxazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2004-03
    Completion
    2010-11
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Diseases; Kidney Transplantation; Kidney Transplant; Renal Transplantation +1 more
    InterventionDaclizumab; Mycophenolate mofetil (MMF); Prednisone; Tacrolimus +3 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed Conditions

    NCT00778583 · start 2003-09

    Registered record
    Registry ID
    NCT00778583
    Conditions
    Healthy
    Interventions
    Nitrofurantoin 100 mg capsules
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2003-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNitrofurantoin 100 mg capsules
    PhaseNot applicable
    Registry statusCompleted

  • Food Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg

    NCT00649285 · start 2002-10

    Registered record
    Registry ID
    NCT00649285
    Conditions
    Healthy
    Interventions
    Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg; Macrobid® Capsules 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-10
    Completion
    2002-11
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg; Macrobid® Capsules 100 mg
    PhasePhase 1
    Registry statusCompleted

  • Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg

    NCT01018342 · start 2002-07

    Registered record
    Registry ID
    NCT01018342
    Conditions
    Healthy
    Interventions
    Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg; Macrobid® Capsules 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2002-07
    Completion
    Not recorded
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg; Macrobid® Capsules 100 mg
    PhasePhase 1
    Registry statusCompleted